Rigel Pharmaceuticals recently issued full-year 2026 guidance, projecting total revenue of about US$275 million to US$290 ...

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) is one of the Best Performing Affordable Stocks Under $40. On January 12, Rigel ...

Rigel Pharmaceuticals (RIGL) recently issued full year 2026 guidance, indicating anticipated total revenue of about US$275 ...

CEO Raul Rodriguez highlighted "year-over-year net product sales growth of 68%" and total revenue of $53.3 million for Q1 2025. He noted that Rigel achieved $11.4 million in net income for the quarter ...

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and ...

CEO Raul Rodriguez highlighted, “For the third quarter, we reported total revenue of $69.5 million, including record net product sales of $64.1 million, a 65% year-over-year increase.” He noted that ...

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with ...

Rigel’s IRAK1/4 inhibitor, R289, has shown promising results in a Phase 1b trial for relapsed/refractory lower-risk myelodysplastic syndrome (LR-MDS). The initial data presented at ASH 2024 ...

SOUTH SAN FRANCISCO, Calif., Oct. 10, 2022 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (RIGL) today announced that it has received guidance from the U.S. Food and Drug Administration (FDA)'s review of ...

Here's why this stock's big run-up in recent months could be just the beginning. A new collaboration deal with a big pharmaceutical company isn't the only reason to keep an eye on this often ...

Investors cheered the latest business update, including a surprise move into an exciting area of research. But it's close enough, and somewhat eases concerns over the drug's sluggish launch. Perhaps ...